| abstract |
The present invention provides novel compounds represented by the general formula I.whereinm is an integer of from 1 to 3;n is 0 or an integer of from 1 to 4;R is selected from the group consisting of CO2H, CO2 R6, CH2OH, CH2O R6 and CONR3R4;R1 and R2 are independently selected from the group consisting of H, R6, C1-C6 alkenyl, C1-C6 alkynyl, C3-C7 cycloalkyl, C4-C12 alkylcycloalkyl, C6-C10 aryl, C7-C12 alkyl aryl radicals and heteroatom-substituted derivatives thereof, wherein one or more of the hydrogen or carbon atoms in said radicals is replaced with a halogen, nitrogen or sulfur-containing radical;R3 and R4 are selected from the group consisting of H and R6; andX is selected from the group consisting of R6, hydroxy, N(R6)2, CON(R6)2, SR6, sulfoxy, sulfone, halogen, COOR6, NO2, CN and OR6, wherein R6 is C1-C6 alkyl, and pharmaceutically acceptable salts thereof. The novel compounds are PGF2alpha antagonists, useful in pharmaceutical compositions for treating PGF2alpha-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis. |